Cancers, Vol. 15, Pages 185: Tumor Response, Disease Control, and Progression-Free Survival as Surrogate Endpoints in Trials Evaluating Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Study- and Patient-Level Analyses

Figure 1. Kaplan–Meier estimates of overall survival based on response evaluation after two cycles and based on 1-year progression-free survival. Responded, complete response, and partial response; controlled, complete response, partial response, and disease control. HR, hazard ratio; brackets, 95% confidence interval.

Figure 1. Kaplan–Meier estimates of overall survival based on response evaluation after two cycles and based on 1-year progression-free survival. Responded, complete response, and partial response; controlled, complete response, partial response, and disease control. HR, hazard ratio; brackets, 95% confidence interval.

Cancers 15 00185 g001

Figure 2. Study-level correlation. Each circle represents one randomized trial. Circle size represents study weight. Red circles indicate the point-symmetry of the original samples (black circles) to produce reciprocal duplication. N, number of trials; r, weighted rank correlation coefficient. ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival.

Figure 2. Study-level correlation. Each circle represents one randomized trial. Circle size represents study weight. Red circles indicate the point-symmetry of the original samples (black circles) to produce reciprocal duplication. N, number of trials; r, weighted rank correlation coefficient. ORR, objective response rate; DCR, disease control rate; PFS, progression-free survival.

Cancers 15 00185 g002

Figure 3. Study level-surrogacy following reciprocal duplication, subgroup analysis. Each circle represents one trial. Circle size represents study weight. Red circles indicate the point-symmetry of the original samples (black circles) for reciprocal duplication. N, number of trials; r, weighted rank correlation coefficient. ORR, odds ratio; DCR, disease control rate; PFS, progression-free survival. 1L, first-line subgroup; 2L-, second- or later-line subgroup.

Figure 3. Study level-surrogacy following reciprocal duplication, subgroup analysis. Each circle represents one trial. Circle size represents study weight. Red circles indicate the point-symmetry of the original samples (black circles) for reciprocal duplication. N, number of trials; r, weighted rank correlation coefficient. ORR, odds ratio; DCR, disease control rate; PFS, progression-free survival. 1L, first-line subgroup; 2L-, second- or later-line subgroup.

Cancers 15 00185 g003

Table 1. Patient characteristics for independent patient data analysis.

Table 1. Patient characteristics for independent patient data analysis.

1st Line2nd or Later LineN20031309Age (year)64 (58–70)63 (57–70)Sex  Men1328 (66.3%)803 (61.3%) Women675 (33.7%)506 (38.7%)Race  Asian199 (9.9%)199 (15.2%) Black or African American36 (1.8%)24 (1.8%) White1693 (84.5%)1027 (78.5%) Other/unknown75 (3.7%)59 (4.5%)Pathology  Squamous677 (33.8%)364 (27.8%) Non-squamous1309 (65.4%)945 (72.2%) Unknown17 (0.8%)0 (0.0%)Stage  IA60 (3.0%)39 (3.0%) IB44 (2.2%)56 (4.3%) IIA46 (2.3%)49 (3.7%) IIB48 (2.4%)75 (5.7%) IIIA134 (6.7%)193 (14.7%) IIIB96 (4.8%)159 (12.1%) IV (not specified for A/B)1489 (74.3%)55 (4.2%) IVA27 (1.3%)310 (23.7%) IVB24 (1.2%)346 (26.4%) Unknown35 (1.7%)27 (2.1%)TD-L1 (IC)  0–0.9917 (45.8%)326 (24.9%) 1–4.9645 (32.2%)315 (24.1%) 5–9.9212 (10.6%)207 (15.8%) 10–49.9191 (9.5%)321 (24.5%) 50–10038 (1.9%)131 (10.0%) Unknown0 (0.0%)9 (0.7%)PD-LI (TC)  0–0.91229 (61.4%)550 (42.0%) 1–4.9205 (10.2%)292 (22.3%) 5–9.973 (3.6%)61 (4.7%) 10–49.9241 (12.0%)181 (13.8%) 50–100255 (12.7%)218 (16.7%) Unknown0 (0.0%)7 (0.5%)Smoking history  Never290 (14.5%)239 (18.3%) Previous1224 (61.1%)901 (68.8%) Current489 (24.4%)169 (12.9%)

Table 2. Characteristics of trials used in the study-level analysis.

Table 2. Characteristics of trials used in the study-level analysis.

CountryPhasePathoStagePD-L1 StatusDriverPSLineImaging EvaluationTreatmentROB
H/U/LAntonia (2017)
PACIFICUSAIIINSCLCIIIa, IIIbAnyANY0–1After CCRRECIST
ICRDur (10 mg/kg) q2w
No active treatment0/0/6Barlesi (2018)
JAVELIN Lung 200South KoreaIIINSCLCIIIb, IV, RecTC > 1%EGFR(-), ALK(-)0–12–4RECIST
ICRAvel (10 mg/kg) q2w
Dtx (75 mg/m2) q3w1/0/5Borghaei (2015)
CheckMate057USAIIINSQIIIb, IVAnyAny0–12–3RECISTNiv (3 mg/kg) q2w
Dtx (75 mg/m2) q3w2/0/4Boyer (2021)
KEYNOTE-598AustraliaIIINSCLCIVTC > 50%EGFR(-), ALK(-)0–11RECIST,
ICRPemb (200 mg) q3w + Ipi (1 mg/kg) q6w
Pemb (200 mg) q3w 0/0/6Brahmer (2015)
CheckMate017USAIIISQIIIb, IVAnyAny0–12RECIST, Niv (3 mg/kg) q2w
Dtx (75 mg/m2) q3w2/0/4Carbone (2017)
CheckMate026USAIIINSCLCIV, RecTC > 5%EGFR(-), ALK(-)0–11RECIST,
ICRNiv (3 mg/kg) q2w
Platinum doublet1/0/5Fehrenbacher (2016)
POPLARUSAIINSCLCAdv, MetAnyAny0–12–3RECISTAtz (1200 mg) q3w
Dtx (75 mg/m2) q3w2/0/4Gandhi (2018)
KEYNOTE-189USAIIINSQMetAnyEGFR(-), ALK(-)0–11RECIST,
ICRPemb (200 mg) + Platinum + Pemt (500 mg/m2) q3w
Platinum + Pemt (500 mg/m2) q3w1/0/5Gettinger (2021)
Lung-MAP S1400I USAIIISQIVAnyAny0–1 (Z)2-RECISTNiv (3 mg/kg) q2w + Ipi (1 mg/kg) q6w
Niv (3 mg/kg) q2w 2/0/4Govindan (2017)
Study 104USAIIISQIV, RecAnyAny0–11mWHOIpi (10 mg/kg) + Cbdca (AUC 6) + Ptx (175 mg/m2) q3w
Cbdca (AUC 6) + Ptx (175 mg/m2) q3w 0/0/6Hellmann (2019)
CheckMate227USAIIINSCLCIV, RecTC >1%EGFR(-), ALK(-)0–11RECIST
ICRNiv (3 mg/kg) q2w + Ipi (1 mg/kg) q6w
Platinum doublet1/0/5Hensing (2021)
Alliance 09USAIINSCLCIVAnyEGFR(-), ALK(-)0–1no previous ICIRECIST,
ICRCbdca doublet q3w x4 followed by Pemb (200 mg) q3w x4
Pemb (200 mg) q3w x4 followed by Cbdca doublet q3w x41/0/5Herbst (2016)
KEYNOTE-010USAII/IIINSCLCAdvTC >1%Any0–12-RECIST,
ICRPemb (10 mg/kg) q3w
Dtx (75 mg/m2) q3w1/0/5Herbst (2020)
IMpower110USAIIINSCLCIVIC>10% or TC>50%EGFR(-), ALK(-)0–11RECISTAtz (1200 mg) q3w
Dtx (75 mg/m2) q3w1/0/5Jotte (2020)
IMpower131USAIIISQIVAnyAny0–11RECISTAtz (1200 mg) + Cbdca (AUC 6) + nPtx (100 mg/m2) q3w
Cbdca (AUC 6) + nPtx (100 mg/m2) q3w1/0/5Jung (2022)
NCT03656094South KoreaIINSCLCAdvAnyEGFR(-), ALK(-)0–12–3RECISTPemb (200 mg) q3w + Single-agent Chemotherpay
Single-agent Chemotherpay0/0/6Langer (2016)
KEYNOTE-021USAIINSQIII, IVAnyEGFR(-), ALK(-)0–11RECISTPemb (200 mg) + Cbdca (AUC 5) + Pemt (500 mg/m2) q3w
Cbdca (AUC 5) + Pemt (500 mg/m2) q3w2/0/4Leighl (2021)
CCTG BR34CanadaIINSCLCIVa, IVbAnyEGFR(-), ALK(-)0–11RECISTDurv (1500 mg) + Trem (75 mg) + Platinum doublet q3w
Durv (1500 mg) + Trem (75 mg) 2/0/4Lynch (2012)
NCT00527735NetherlandsIINSCLCIIIb, IVAnyEGFR(-), ALK(-)0–11mWHO, ICRIpi (10 mg/kg) + Cbdca (AUC 6) + Ptx (175 mg/m2) q3w
Cbdca (AUC 6) + Ptx (175 mg/m2) q3w 0/0/6Mok (2019)
KEYNOTE-042HKIIINSCLCLocAdv, MetTC>1%EGFR(-), ALK(-)0–11RECIST,
ICRPemb (200 mg) q3w
Cbdca doublet1/0/5Nishio (2021)
IMpower132JapanIIINSQIVAnyAny0–11RECISTAtz (1200 mg) + Platinum + Pemt (500 mg/m2) q3w
Platinum + Pemt (500 mg/m2) q3w2/0/4Paz-Ares (2018)
KEYNOTE-407SpainIIISQIVTC >50%Any0–11RECIST,
ICRPemb (200 mg) +Cbdca (AUC 6) + (Ptx (200 mg/m2) or nPtx (100 mg/m2)) q3w
Cbdca (AUC 6) + (Ptx (200 mg/m2) or nPtx (100 mg/m2)) q3w0/0/6Paz-Ares (2021)
CheckMate9LASpainIIINSCLCIV, RecAnyEGFR(-), ALK(-)0–11RECIST,
ICRNiv (360 mg) q3w + Ipi (1 mg/kg) q6w + Platinum doublet q3w
Platinum doublet q3w1/0/5Planchard (2020)
ARCTIC-AFranceIIINSCLCIIIb, IVTC >25%EGFR(-), ALK(-)0–13-RECISTDurv (10 mg/kg) q2w
Gem and Vin or Erl2/0/4Planchard (2020)
ARCTIC-BFranceIIINSCLCIIIb, IVTC <25%EGFR(-), ALK(-)0–13-RECISTDurv (20 mg/kg) + Trem (1 mg/kg) q4w
Gem and Vin or Erl2/0/4Reck (2016)
KEYNOTE-024USAIIINSCLCIVTC>50%EGFR(-), ALK(-)0–11RECIST,
ICRPemb (200 mg) q3w
Platinum doublet1/0/5Rittmeyer (2017)
OAKUSAIIINSCLCIIIb-IVIC>1% or TC>1%Any0–12–3RECISTAtz (1200 mg)
Dtx (75 mg/m2) q3w2/0/4Rizvi (2020)
MYSTICUSAIIINSCLCIVTC>25%EGFR(-), ALK(-)0–11RECIST,
ICRDurv (20 mg/kg) q4w
Platinum doublet1/0/5Sezer (2021)
EMPOWER-Lung 1TurkeyIIINSCLCIIIb, IIIc, IVTC >50%EGFR(-), ALK(-), ROS1(-)0–11RECIST,
ICRCemi (350 mg) q3w
Platinum doublet1/0/5Socinski (2018)
IMpower150GermanyIIINSQIV, RecAnyEGFR(-), ALK(-)0–11RECIST,
ICRAtz (1200 mg) + Bev (15 mg/kg) + Cbdca (AUC 6) + Ptx (200 mg/m2)
Bev (15 mg/kg) + Cbdca (AUC 6) + Ptx (200 mg/m2)1/0/5Sugawara (2021)
ONO-4538-52/TASUKI-52JapanIIINSQIIIb, IVAnyEGFR(-), ALK(-), ROS1(-)0–11RECIST,
ICRNiv (360 mg) + Cbdca (AUC 6) + Ptx (200 mg/m2) + Bev (15 mg/kg)
Cbdca (AUC 6) + Ptx (200 mg/m2) + Bev (15 mg/kg)0/0/6West (2019)
IMpower130ItalyIIINSQIVAnyEGFR(-), ALK(-)0–11RECIST,
ICRAtz (1200 mg) q3w + Cbdca (AUC 6) q3w + nPtx (100 mg/m2) q1w
Cbdca (AUC 6) q3w + nPtx (100 mg/m2) q1w1/0/5Wu (2019)
CheckMate078ChinaIIINSCLCIIIb, IVAnyEGFR(-), ALK(-)0–12RECISTNiv (3 mg/kg) q2w
Dtx (75 mg/m2) q3w2/0/4Yang (2020)
ORIENT-11 ChinaIIINSQIIIb, IIIc, IVAnyEGFR(-), ALK(-)0–11RECISTSint (200 mg) + Platinum +Pemt (500 mg/m2) q3w
Platinum + Pemt (500 mg/m2) q3w0/0/6ZhouC (2021)
ORIENT-12ChinaIIISQIIIb, IIIc, IVAnyEGFR(-), ALK(-)0–11RECIST,
ICRSint (200 mg) + Platinum +Gem (1000 mg/m2, d 1, 8) q3w
Platinum +Gem (1000 mg/m2, d 1, 8) q3w0/0/6ZhouC (2022)
GEMSTONE-302ChinaIIINSCLCIVAnyEGFR(-), ALK(-), ROS1(-), RET(-)0–11RECIST,
ICRSuge (1200 mg) + Cbdca doublet q3w
Cbdca doublet q3w0/0/6ZhouQ (2022)
GEMSTONE-301ChinaIIINSCLCIIIAnyEGFR(-), ALK(-), ROS1(-)0–1After CCRRECIST,
ICRSuge (1200 mg)
No active treatment0/0/6ZhouC (2021)
CameLChinaIIINSQIIIb, IVAnyEGFR(-), ALK(-)0–11RECIST,
ICRCamr (200 mg) + Cbdca (AUC 5) + Pemt (500 mg/m2) q3w
Cbdca (AUC 5) + Pemt (500 mg/m2) q3w1/0/5

留言 (0)

沒有登入
gif